U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H14N7O5S4.Na
Molecular Weight 535.576
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFUZONAM SODIUM

SMILES

[Na+].[H][C@]12SCC(CSC3=CN=NS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C([O-])=O

InChI

InChIKey=BCMSQWPLFBUUKW-IXLPVNPSSA-M
InChI=1S/C16H15N7O5S4.Na/c1-28-21-9(7-5-31-16(17)19-7)12(24)20-10-13(25)23-11(15(26)27)6(4-30-14(10)23)3-29-8-2-18-22-32-8;/h2,5,10,14H,3-4H2,1H3,(H2,17,19)(H,20,24)(H,26,27);/q;+1/p-1/b21-9-;/t10-,14-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C16H14N7O5S4
Molecular Weight 512.586
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED
Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/3322588

Cefuzoname (CZON, L-105) is a second-generation cephalosporin antibiotic, has broad spectrum on Gram-positive or -negative bacteria and may also be effective against Staphylococcus aureus against which third generation cephalosporins are largely ineffective.

CNS Activity

CNS Penetrant
2554
Curator's Comment: CNS penetrant in rabbits and humans http://www.ncbi.nlm.nih.gov/pubmed/3613085

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Klebsiella pneumoniae growth
4
Target ID: Klebsiella pneumoniae growth
Inhibitor
8297
Escherichia coli growth
23
Target ID: Escherichia coli growth
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Preclinical
Unknown

Approved Use

Unknown
Curative
Preclinical
Unknown

Approved Use

Unknown
Curative
Preclinical
Unknown

Approved Use

Unknown
Curative
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Fundamental and clinical studies on cefuzoname in the pediatric field].
1987 Apr
[Clinical evaluation of cefuzonam (CZON) for bacterial pneumonia and lung abscess: comparative study with cefotiam (CTM)].
1991 Apr
Bone cement not weakened by cefuzonam powder.
1991 Jun
[Clinical studies on cefuzonam for acute peritonitis due to perforated appendicitis. Tissue concentration and clinical efficacy].
1991 Sep
Patents

Patents

JP2002541233A
400
JP2003515526A
462
JPS60120886A
2

Sample Use Guides

In Vivo Use Guide
Cefuzonam in a dose of 1 g was administered by intravenous bolus injection or intravenous drip infusion for 60 minutes.
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: The MIC80's against Serratia marcescens and Enterobacter aerogenes were both 6.25 ug/ml, and that against Pseudomonas aeruginosa was 100 ug/ml. The MIC80's against Staphy-lococcus epidermidis were 25 and 6.25 ug/ml, respectively. Approximately 70% of strains of S. aureus were inhibited at concentrations less than 1.56 ug/ml.
The MIC80's of cefuzonam against Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Haemophilus influenzae and Citrobacter spp. were less than 0.20 ug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:36:30 GMT 2023
Edited
by admin
on Fri Dec 15 18:36:30 GMT 2023
Record UNII
6SOU25L22C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFUZONAM SODIUM
JAN   WHO-DD  
Common Name English
SODIUM CEFUZONAM
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2Z)-2-(2-AMINO-4-THIAZOLYL)-2-(METHOXYIMINO)ACETYL)AMINO)-8-OXO-3-((1,2,3-THIADIAZOL-5-YLTHIO)METHYL)-, SODIUM SALT (1:1), (6R,7R)-
Common Name English
Cefuzonam sodium [WHO-DD]
Common Name English
CEFUZONAM SODIUM [JAN]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-8-OXO-3-((1,2,3-THIADIAZOL-5- YLTHIO)METHYL)-, SODIUM SALT, (6R-(6-ALPHA,7-BETA(Z)))-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID40231634
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
EVMPD
SUB01141MIG
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
PUBCHEM
23663965
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
FDA UNII
6SOU25L22C
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
SMS_ID
100000084685
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
NCI_THESAURUS
C98232
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
CAS
82219-81-6
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL1689069
Created by admin on Fri Dec 15 18:36:30 GMT 2023 , Edited by admin on Fri Dec 15 18:36:30 GMT 2023
PRIMARY
Related Record Type Details
Structure of CEFUZONAM
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CEFUZONAM
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966